Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288015 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Treating Patients With Angiosarcoma
A Phase 2 study of Sarcoma, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 5
- Study locations
NCT00288015 is a Phase 2 study of Sarcoma that has completed, run by Northwestern University. The registered enrollment target is 32 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00288015, a Phase 2 study of Sarcoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with angiosarcoma.
Conditions Studied
Interventions
- BIOLOGICAL Bevacizumab
Study Locations (5)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Minnesota
- Mayo Clinic Cancer Center - Rochester
Pennsylvania
- Fox Chase Cancer Center CCOP Research Base - Philadelphia
Texas
- M. D. Anderson Cancer Center at University of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-10 |
| Est. Completion | 2016-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288015
The ClinicalTrials.gov registry entry for NCT00288015 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab is the first listed.
NCT00288015 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00288015 about?
NCT00288015 is a clinical study titled "Bevacizumab in Treating Patients With Angiosarcoma". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by bloc...
What is the current status of trial NCT00288015?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2005-10. Estimated completion is 2016-11-10.
What conditions does trial NCT00288015 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00288015?
The interventions under investigation include: Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00288015?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00288015 being conducted?
This trial has 5 study locations across California, Illinois, Minnesota, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.